Subcellular Localization of Total and Activated Src Kinase in African American and Caucasian Breast Cancer

被引:33
作者
Anbalagan, Muralidharan [1 ]
Moroz, Krzysztof [2 ]
Ali, Alaa [1 ]
Carrier, Latonya [1 ]
Glodowski, Seth [1 ]
Rowan, Brian G. [1 ]
机构
[1] Tulane Univ, Sch Med, Dept Struct & Cellular Biol, New Orleans, LA 70112 USA
[2] Tulane Univ, Sch Med, Sect Surg Pathol & Cytopathol, New Orleans, LA 70112 USA
基金
美国国家卫生研究院;
关键词
RECEPTOR TYROSINE KINASES; C-SRC; FAMILY KINASES; PROTEIN EXPRESSION; TARGETING SRC; CELLS; IDENTIFICATION; PATHWAYS; TUMORS; CHEMOSENSITIVITY;
D O I
10.1371/journal.pone.0033017
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Src, a non-receptor tyrosine kinase is elevated in cancer with expression and activity correlated with cell proliferation, adhesion, survival, motility, metastasis and angiogenesis. There is limited data on Src expression and subcellular localization in breast cancer and no information about expression in racial/ethnic groups. Methodology/Principal Findings: The present study evaluated Src expression, activity, and subcellular localization in triple negative breast cancer (TNBC) and ER alpha positive breast cancer (ER+BC), cancer tissue and adjacent normal epithelial ducts, and Caucasian and African American cases. 79 paraffin embedded breast carcinoma cases were obtained from Tulane University Hospital between 2007-2009. 39 cases represented TNBC (33-African Americans, 4-Caucasians, 2-unknowns) and 40 cases represented ER+BC (21-African Americans, 16-Caucasians, 3-unknowns). Immunohistochemistry was used to measure staining distribution and intensity of total Src and activated phospho-SrcY416 (p-Y416Src) in carcinoma tissue and adjacent normal mammary ducts. In TNBC and ER+BC, total Src was significantly higher in cancer compared to adjacent normal ducts (P < 0.0001) in both cell membrane and cytoplasm. In membranes, p-Y416Src was elevated in cancer compared to normal ducts. Total Src in the tumor cytoplasm was significantly higher in TNBC compared to ER+BC (P = 0.0028); conversely, p-Y416Src in the tumor cell membranes was higher in TNBC compared to ER+BC (P = 0.0106). Comparison between African American (n = 21) and Caucasian ER+BC (n = 16) revealed no significant difference in expression and localization of total Src and p-Y416Src. TNBC cases positive for lymph node metastasis showed elevated membrane p-Y416Src compared to lymph node negative TNBC (P = 0.027). Conclusion/Significance: Total Src and p-Y416Src were expressed higher in cancer compared to adjacent normal ducts. Cytoplasmic total Src and membrane p-Y416Src were significantly higher in TNBC compared to ER+BC. TNBC cases with lymph node metastasis showed elevated membrane p-Y416Src. Taken together, Src was elevated in the membrane and cytoplasm of more aggressive TNBC.
引用
收藏
页数:10
相关论文
共 42 条
[1]   Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways [J].
Acosta, JJ ;
Muñoz, RM ;
González, L ;
Subtil-Rodríguez, A ;
Domínguez-Cáceres, MA ;
García-Martínez, JM ;
Calcabrini, A ;
Lazaro-Trueba, I ;
Martín-Pérez, J .
MOLECULAR ENDOCRINOLOGY, 2003, 17 (11) :2268-2282
[2]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[3]  
Anbalagan M, 2011, BREAST CANC RES TREA
[4]  
Bolós V, 2010, ONCOTARGETS THER, V3, P83
[5]   The interplay between Src family kinases and receptor tyrosine kinases [J].
Bromann, PA ;
Korkaya, H ;
Courtneidge, SA .
ONCOGENE, 2004, 23 (48) :7957-7968
[6]   Search for New Treatments Intensifies for Triple-Negative Breast Cancer [J].
Brower, Vicki .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (22) :1536-1537
[7]   Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer [J].
Campbell, E. J. ;
McDuff, E. ;
Tatarov, O. ;
Tovey, S. ;
Brunton, V. ;
Cooke, T. G. ;
Edwards, J. .
BRITISH JOURNAL OF CANCER, 2008, 99 (11) :1769-1774
[8]   Triple-negative breast cancer: disease entity or title of convenience? [J].
Carey, Lisa ;
Winer, Eric ;
Viale, Giuseppe ;
Cameron, David ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (12) :683-692
[9]   The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].
Carey, Lisa A. ;
Dees, E. Claire ;
Sawyer, Lynda ;
Gatti, Lisa ;
Moore, Dominic T. ;
Collichio, Frances ;
Ollila, David W. ;
Sartor, Carolyn I. ;
Graham, Mark L. ;
Perou, Charles M. .
CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334
[10]   Triple-negative breast cancer: therapeutic options [J].
Cleator, Susan ;
Heller, Wolfgang ;
Coombes, R. Charles .
LANCET ONCOLOGY, 2007, 8 (03) :235-244